PBAC's latest decision on Fosnetupitant with palonosetron: Recommended with restriction (2020). Considered for Prevention of nausea and vomiting associated with cytotoxic chemotherapy in patients receiving moderately and highly emetogenic chemotherapy, including anthracycline plus cyclophosphamide-based regimens.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Patients receiving moderately or highly emetogenic chemotherapy, including women with breast cancer receiving anthracycline plus cyclophosphamide-based chemotherapy regimens, requiring anti-emetic prophylaxis.
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Key trials
PNET-12-23, PALO-15-17, NEPA-15-18, NEPA-17-05
Comparator
lowest cost combination of a NK1 RA (aprepitant or fosaprepitant) with a 5HT3 RA
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. NEPA IV cost-minimised to the lowest cost NK1 RA + 5HT3 RA combination at equi-effective doses.